Patents by Inventor Mark J. Gilbert
Mark J. Gilbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10507219Abstract: Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.Type: GrantFiled: October 20, 2015Date of Patent: December 17, 2019Assignee: JUNO THERAPEUTICS, INC.Inventor: Mark J. Gilbert
-
Publication number: 20190277858Abstract: Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS.Type: ApplicationFiled: December 2, 2016Publication date: September 12, 2019Applicants: Juno Therapeutics, Inc., Fred Hutchinson Cancer Research CenterInventors: He LI, Mark J. GILBERT, David MALONEY, Stanley R. RIDDELL, Cameron J. TURTLE
-
Publication number: 20190099418Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: October 1, 2018Publication date: April 4, 2019Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Howard S. ROTH, Theodore M. TARASOW
-
Publication number: 20190099419Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: October 1, 2018Publication date: April 4, 2019Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Avadhut JOSHI, Gregory J. RIGGINS, Theodore M. TARASOW
-
Patent number: 10085977Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: July 26, 2016Date of Patent: October 2, 2018Assignees: The Board of Trustees of the Univerity of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Patent number: 10085978Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: August 22, 2016Date of Patent: October 2, 2018Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
-
Patent number: 9592229Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: March 4, 2013Date of Patent: March 14, 2017Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Theodore M. Tarasow
-
Publication number: 20170042886Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: August 22, 2016Publication date: February 16, 2017Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael J. Handley, Avadhut JOSHI, Gregory J. RIGGINS, Theodore M. TARASOW
-
Publication number: 20160346277Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: July 26, 2016Publication date: December 1, 2016Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Howard S. ROTH, Theodore M. TARASOW
-
Patent number: 9421202Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: March 6, 2013Date of Patent: August 23, 2016Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael J. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
-
Patent number: 9399035Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: March 6, 2013Date of Patent: July 26, 2016Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Publication number: 20160206656Abstract: Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.Type: ApplicationFiled: October 20, 2015Publication date: July 21, 2016Applicant: JUNO THERAPEUTICS, INC.Inventor: Mark J. GILBERT
-
Publication number: 20160158359Abstract: Provided are methods for multiple administrations of cells for adoptive cell therapy, and for administering cells to subjects having received prior administrations, and compositions and articles of manufacture for use in the methods. The cells generally express recombinant molecules such as recombinant receptors, e.g., chimeric antigen receptors (CARs) and/or other transgenic receptors. The methods can involve administering cells expressing a first or prior receptor(s) and cells expressing a second or subsequent receptor(s), the second or subsequent receptor(s) being distinct from the first, and which generally do not express the first receptor, and/or administering the cells expressing the second receptor to a subject having received the first administration.Type: ApplicationFiled: December 3, 2015Publication date: June 9, 2016Applicant: Juno Therapeutics, Inc.Inventor: Mark J. GILBERT
-
Publication number: 20150099759Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: March 4, 2013Publication date: April 9, 2015Applicants: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Theodore M. Tarasow
-
Publication number: 20150025083Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: March 6, 2013Publication date: January 22, 2015Applicants: THE JOHNS HOPKINS UNIVERSITY, VANQUISH ONCOLOGY, INC.Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael J. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
-
Publication number: 20150017264Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: ApplicationFiled: March 6, 2013Publication date: January 15, 2015Applicants: Vanquish Oncology, Inc., TheBoard of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Patent number: 5609741Abstract: A method of manufacturing a composite material in which a fibre matt is placed adjacent a plate electrode in ceramic sol. The application of an electric field to the sol via the electrode results in the deposition of sol particles on the electrode which subsequently permeate the fibre matt. The permeated fibre matt is then removed from the sol, dried out and heated to sinter the sol particles.Type: GrantFiled: October 20, 1994Date of Patent: March 11, 1997Assignee: Rolls-Royce plcInventors: Trevor J. Illston, Paul A. Doleman, Edwin G. Butler, Peter M. Marquis, Clive B. Ponton, Reza Piramoon, Mark J. Gilbert
-
Patent number: 5554271Abstract: A method of manufacturing a composite material which comprises ceramic fibers in a matrix of a ceramic material. A woven mat of ceramic fibers having an electrically conductive coating thereon is immersed in a sol. The sol comprises surface-charged ceramic particles. A potential difference is applied between the fibers and a second electrode placed in the sol. The applied potential difference is continued until the mat is permeated by the ceramic particles in the sol. The mat is removed from the sol and is then heated to sinter the permeated ceramic particles.Type: GrantFiled: March 8, 1995Date of Patent: September 10, 1996Assignee: Rolls-Royce plcInventors: Trevor J. Illston, Paul A. Doleman, Edwin G. Butler, Peter M. Marquis, Clive B. Ponton, Reza Piramoon, Mark J. Gilbert